As GlaxoSmithKline works to get Shingrix back on track, an FDA approval increases the key vaccine's reach

In response to the coronavirus pandemic knocking Shingrix off its juggernaut course, GlaxoSmithKline plans a “relaunch” to get the rising star vaccine back on its upward trajectory.

Now, that effort has received a boost as the FDA on Monday approved the shingles vaccine in adults age 18 and older who are immunocompromed and thus are at a greater risk of developing the viral condition that causes a painful rash with blisters.